Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
Work
Year: 2020
Type: article
Source: Journal of Clinical Oncology
Authors Joao V. Alessi, Biagio Ricciuti, Elizabeth Jiménez Aguilar, Fangxin Hong, Zihan Wei +10 more
Institutions Hospital Sírio-Libanês, Dana-Farber Cancer Institute, Biostatistical Consulting (United States), Harvard University, Dana-Farber Brigham Cancer Center +4 more
Cites:
Cited by: 4
Related to: 10
FWCI: 0.381
Citation percentile (by year/subfield): 52.25
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed